M&A
confidence high
sentiment neutral
materiality 0.70
Jazz completes $935M acquisition of Chimerix, adds dordaviprone to pipeline
Jazz Pharmaceuticals plc
- Acquisition completed for ~$935M cash; $8.55 per share.
- Dordaviprone for H3 K27M-mutant diffuse glioma under FDA Priority Review; PDUFA date Aug 18, 2025.
- If approved, could be first FDA-approved therapy for that indication; potential near-term opportunity.
- Also in Phase 3 ACTION trial for newly diagnosed, non-recurrent diffuse glioma.